2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
105
Carcinoma, Hepatocellular
34
Neoplasm Metastasis
19
Neoplasms
17
Gastrointestinal Stromal Tumors
17
Colonic Neoplasms
14
Rectal Neoplasms
12
Liver Neoplasms
8
Glioblastoma
7
Sarcoma
6
Stomach Neoplasms
5
Sarcoma, Ewing
5
Ovarian Neoplasms
5
Osteosarcoma
5
Melanoma
5
Adenocarcinoma
5
Pancreatic Neoplasms
4
Esophageal Neoplasms
4
Cholangiocarcinoma
4
Carcinoma, Renal Cell
4
Carcinoma, Non-Small-Cell Lung
4
Small Cell Lung Carcinoma
3
Rhabdomyosarcoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Leukemia, Myeloid, Acute
3
Colorectal Cancer Metastatic
3
Carcinoma, Transitional Cell
3
Carcinoma
3
Advanced Colorectal Cancer
3
Thyroid Neoplasms
2
Interventions
Lenalidomide
4
Gemcitabine
4
Dexamethasone
4
Cyclophosphamide
4
Bortezomib
4
Nivolumab
3
Cisplatin
3
Carboplatin
3
vandetanib
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
pomalidomide
2
pembrolizumab
2
liposomal doxorubicin
2
fludarabine
2
durvalumab
2
capivasertib
2
Radiosurgery
2
Paclitaxel
2
Doxorubicin
2
Bevacizumab
2
Anthropogenic Effects
2
venetoclax
1
umbralisib
1
ublituximab
1
tremelimumab
1
tivozanib
1
ricolinostat
1
regorafenib
1
pazopanib
1
niraparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
regorafenib
×
Clear all
NCT07514455
2026-04-07
RECOMEND
Asan Medical Center
Phase 2
Not yet recruiting
20 enrolled